Corrigendum to 'Dihydroartemisin inhibits glioma invasiveness via a ROS to P53 to β-catenin signaling' [Pharmacol. Res. 119 (2017) 72–88]

Authors :: Jun Ma
Yi Hu
Yixue Xue
Xiaobai Liu
Yunhui Liu
Zhongyou Que
Chengbin Qu
Ping Wang
Source :: Pharmacological Research. 173:105908
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pharmacology
Chemistry
Glioma
medicine
Cancer research
β catenin signaling
medicine.disease

Tools